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Retinoblastoma (Rb) is considered to represent the prototype of cancer linked to the sequential loss or inactivation of both alleles
of a so-called “tumor suppressor gene”, the Rb1 gene. The pathogenetic mechanism behind this tumor was ﬁrst hypothesized
by Knudson in 1971 and further conﬁrmed by others who identiﬁed the Rb1 gene whose loss or inactivation was claimed to
be responsible for the disease. However, after about four decades of continuous research in the ﬁeld of molecular biology, the
evidence behind the role of the Rb1 gene in Rb appears to be seriously ﬂawed in the light of epidemiological, biological, and
clinical evidences. This editorial summarizes the inconsistencies on this subject. Nevertheless, the molecular biology establishment
still adheres to the biased view of the genetic origin of Rb and other cancers, and hardly any alternative explanations are taken into
account.
Copyright © 2009 Domenico Mastrangelo et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Retinoblastoma(Rb)isthemostcommonintraocularmalig-
nant tumor in childhood, with an incidence of 1 in 15000
live births [1]. It may aﬀect one eye (unilateral Rb) or both
(bilateral Rb) during the ﬁrst ﬁve years of life. Rare cases
have also been reported in young adults [2, 3]. Although
extensive epidemiologic studies have been done to study
this tumor, the results have been more often misinterpreted
at the expense of mutation theory which has prevailed
until recently in spite of the outstanding evidence against
it [4]. In the present review the authors analyze the most
relevant epidemiological issues concerning retinoblastoma,
in the light of recent developments highlighting the role of
aneuploidy and genetic instability [5] in the pathogenesis of
this eye cancer.
2. HistoricalBackground
Themostimportantstudiestoinvestigatethepathogenesisof
retinoblastoma began with a paper published by Knudson in
1971 [6], when the author, after investigating the age distri-
bution and laterality of a cohort of 48Rb patients, concluded
that the disease could be inherited and formulated the so-
called “two-hit theory” in order to explain its pathogenesis.
In reality, no clues about the inheritance of retinoblastoma
could be deducted from such a small sample. In fact, in
his ﬁrst report on this matter, Knudson referred to earlier,
smaller series showing that, in retinoblastoma survivors with
bilateral disease, the proportion of aﬀected oﬀspring closely
approximated 50%, as in dominant (Mendelian) inheritance
[6]. From an original, mathematical analysis of the above
data, Knudson inferred that retinoblastoma is caused by
two sequential (two hit) mutational events. According to
this hypothesis, in the dominantly inherited form of the
disease, one mutation is inherited via the germinal cells
and the second spontaneously occurs in somatic cells of the
retina and other tissues of the body. On the contrary, in the
nonhereditary form, both mutations occur in the somatic
(retinal) cells. The diﬀerent timing and cell type involved by
the two mutations determines the diﬀerent clinical pheno-
type, with all bilateral and a minority of the unilateral cases
being classiﬁed as hereditary, and the remaining unilateral
cases being included in the sporadic group (Table 1). During
the following forty years of epidemiological, clinical, genetic,
and biological research in this ﬁeld, with the discovery2 Journal of Cancer Epidemiology
Table 1: Distribution of retinoblastoma by type and laterality [6].
Bilateral Unilateral Total
Hereditary 25%–30% 10%–15% 35%–45%
Nonhereditary 0 55%–65% 55%–65%
Total 25%–30% 65%–70% 100%
of the Rb1 as the prototype tumor suppressor gene, the
medical establishment agreed on the pathogenetic “two-
hit” theory which was further expanded by Knudson, in
many other scientiﬁc articles and review papers [6–24]. This
generatedthewidespreadconvictionthatRbiscausedbytwo
mutational events leading to the loss or inactivation of both
alleles of the Rb1 gene, as still believed by some authors [25].
3. The Weak Foundations of the
“Two-Hit”Theory
As mentioned above, the original input into the possible
genetic derivation of retinoblastoma was based on limited
evidence showing an apparently dominant Mendelian distri-
bution of the disease in the oﬀspring of bilaterally aﬀected
individuals,thusallowingKnudsontoconcludethatbilateral
Rb is inherited through the germ cells. Minimum or no
disagreement had been appeared on this account in the
literature during the last four decades.
In an attempt to elucidate this issue, we have performed
an analysis of the distribution of the disease in the oﬀ-
spring of unilaterally aﬀected Rb survivors, referred to the
Department of Ophthalmology—Ocular Oncology Unit at
the University of Siena in Siena, Italy. We discovered that
in a total of 16 children born to 12 unilaterally aﬀected
patients, 8 (50%) were healthy and 8 (50%) aﬀected with Rb
(Table 2). Using the reasoning of Knudson, it would be easily
concluded that the unilateral disease phenotype is inherited
and not sporadic, and this would be in sharp contrast with
the current knowledge according to which bilateral Rb is
“always” hereditary and unilateral Rb is “almost always”
sporadic.
4. FamilialRb with UnilateralPhenotype:
Is There Any Explanation?
It was reported by Knudson [6] and conﬁrmed by others
[26] that about 10% of all Rb cases do have a “positive
family history”. In other words, the family history of the
“index” case oﬀers at least one other aﬀected member, either
a parent or another close relative. In this case, it is assumed
that the events leading to the inactivation of the Rb1 gene
run in the family, and therefore the ﬁrst “hit” is transmitted
through the germline, exactly what happens in bilateral Rb,
but with one diﬀerence; bilateral Rbs, which after Knudson
arealltobeconsidered“hereditary”,arealsoassumedtohave
inherited the “ﬁrst hit” through a mutation in one of the
parent’s germ cells, but they are the only aﬀected members in
their families. We should therefore be reasoning that, since
familial Rbs share the same pathogenetic mechanism with
Table 2: A list of 36 retinoblastoma survivors and their oﬀspring
referred to the Ocular Oncology Unit of the Department of
Ophthalmology of the University of Siena (Italy). Unilaterally
aﬀected survivors generated a total of 16 children, half of which
resulted aﬀected.
Patient’s number Lat. Oﬀspring
Number of healthy Number of aﬀected
1B 1
2B 2 1
3B 1 2
4U 1 2
5B 2
6B 2 1
7B 1
8B 2 1
9B 1 1
10 B 1
11 B 2
12 U 1
13 B 1
14 B 1
15 B 1
16 B 1
17 U 1
18 B 1
19 B 1
20 B 1
21 U 1
22 U 1
23 U 1
24 B 1
25 U 1
26 U 1
27 B 1
28 B 1
29 B 1
30 U 3
31 B 2
32 B 1
33 B 1
34 U 1
35 U 1
36 U 1
bilateral (hereditary) Rb, the vast majority of these cases
should show the bilateral phenotype. To be more accurate,
we could make a calculation of the percentage of familial Rbs
carryingtheunilateralphenotype.Asamatteroffact,Table 1
shows that the unilateral phenotype accounts for about 1/3
of all hereditary cases (or about 30%), and since familial
Rb represents the 10% of all Rbs, it comes out that Rbs
carrying the unilateral phenotype, within the familial group,
should not be more than 3% (i.e., the 30% of the 10%). As a
matter of fact, a meta-analysis of a cohort of 3584 patientsJournal of Cancer Epidemiology 3
Table 3: A meta-analysis of literature shows that within a total
of 344 familial retinoblastoma, 83 (23%) showed the unilateral
phenotype.
Author uRB bRB Tot. Fam. U Fam. B Tot. Fam.
Abramson 626 905 1531 36 150 186
Gunalp 441 195 636 10 24 34
Sanders 282 149 431 15 38 53
Matzunaga 403 196 599 11 17 28
Hadjistilianou 227 160 387 11 32 43
Tot. 1979 1605 3584 83 261 344
(23%) (77%)
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Figure 1: The distribution of retinoblastoma by laterality in a
sample of 387 patients referred to the Ocular Oncology Unit
of the Department of Ophthalmology of the University of Siena
(Italy). Five cases, diagnosed beyond the age of 87 months, are not
reported in the diagram. As it can be appreciated, the distribution
of unilateral Rb by age at diagnosis is highly skewed, and therefore,
the calculation of the “mean” in this sample may lead to unreliable
inferences.
(Table 3), reported by us elsewhere [4, 5], reveals that on
a total of 344 (9.5%) familial cases, 83 (24%) show the
unilateral phenotype, instead of the predicted 3%, a rather
unexplainable ﬁgure, in the light of the predictions made by
the “two hit” hypothesis.
5.13qDeletion Syndrome:A Caseagainstand
Not inFavourof the “Two-Hit”Hypothesis
In 1986, Potluri and coworkers observed that the association
of Rb with the constitutional chromosome 13q deletion syn-
drome and the ﬁnding of 13q deletions or monosomy 13 in
Rbcellsinindividualswithnormalconstitutionalkaryotypes
seemedtosuggestthatchromosome13qcouldcontainagene
responsible for tumor development in retinoblastoma [27].
Although the authors themselves acknowledged that other
chromosome abnormalities, in addition to those involving
chromosome 13, are evident in retinoblastoma (additional
copies of 1q material in 44% of cases, isochromosome 6p, in
45% of cases, monosomy 16, in 18% of cases, marker 1p+, in
13% of cases, and homogeneously staining regions and dou-
ble minutes, in 9% of cases), further investigations on this
matter stressed the role of 13q deletions in the genesis of Rb
Table 4: 13 cases of 13q deletion syndrome referred to the
Ocular Oncology Unit of the Department of Ophthalmology of
the University of Siena (Italy). 9/13 expressed the unilateral disease
phenotype. The calculation of the mean age at diagnosis reveals a
value of 10 months.
Patient Gender Age at diagnosis Laterality
Z. A. F 9 m B
B. S. M 5 m B
V. F. F 16 m U
D. D. C. F 10 m B
S. G. F 29 m U
M.C. M 10 m U
F. I. F 5 m U
Z. S. M 8 m U
P. R. F 8 m U
P. A M 12 m U
Z. M. F 5 m U
Z. E. F 9 m U
L. I. F 5 m B
[28], thus reinforcing the belief that the loss or inactivation
of the Rb1 was the only responsible for Rb to develop. But it
is well known that retinoblastoma is only one among many
diﬀerent tumors associated with deletions of chromosome
13. Cancers linked with these deletions include chronic lym-
pocytic leukaemia (CLL) [29], chronic myeloproliferative
disorders [30], multiple myeloma [31], hepatocellular carci-
noma (HCC) [32], nasopharyngeal carcinoma [33], benign
and low-grade malignant lipomatous tumors [34], bladder
cancer [35], malignant mesothelioma [36], and prostate
cancer [37]. The same pleiomorphism in the phenotypic
expression of cancers associated with Rb1 gene mutations
[38] is therefore evident in 13q deletion syndrome.
But the most important consideration to be made about
the association of 13q deletion syndrome and Rb concerns
the evident discrepancy existing between the expected and
the real number of bilateral tumors among the patients
aﬀected by this genetic disorder. As a matter of fact, the 13q
deletion syndrome must be conﬁrmed by the cytogenetic
analysis of peripheral blood lymphocytes, and it is due to
a “constitutional” deletion of the long arm of chromosome
13 which involves, by deﬁnition, the Rb1 gene locus. Since
the “constitutional” deletion of the Rb1 gene can only be
present if transmitted through the germ cells of one parent,
it follows that all patients aﬀected by 13q deletion syndrome
and retinoblastoma belong to the “hereditary” group of
Knudson’s and must, therefore, express the bilateral disease
phenotype. It happens, however, that this assumption does
not ﬁt the clinical reality. In Table 4 a series of 13 cases of 13q
deletionsyndromeandretinoblastomareferredtousoverthe
last four decades is reported. Of these patients, only 4 had
the bilateral disease phenotype, while the remaining 9 were
unilaterally aﬀected (Table 4). The mean age at diagnosis
in this group, which is about 10 months, further reinforces
the assumption that they must belong to the “hereditary”
group of Knudson’s, but the unilateral disease phenotype is4 Journal of Cancer Epidemiology
unexplainably high. In the light of the “two hit” theory, the
data summarized above do not have any rationalization, and
the only plausible conclusion is that the assumptions made
in regard to the role of the Rb1 gene in retinoblastoma are
incorrect.
6. Concluding Remarks
Clinical Epidemiology is a leading discipline in the under-
standing of disease pathogenesis and etiology, but, as any
other scientiﬁc endeavor, it relies on the correct interpreta-
tion of the available data. The proper analysis of data, in
turn, relies not only on the individual researcher’s skill but
also on social, economic, and political environment in which
thedataareanalyzed.ThepresumedgeneticoriginofRband
its relationship with the Rb1 gene represent a clear example
of how an entire body of prominent researchers may fail to
questionaﬂawedpathogenetichypothesis(i.e.,the“two-hit”
theory),forthesakeofpersonal,academic,orotherinterests.
I tw a sn o tb yc h a n c et h a tw eh a dt oa p p r o a c hm a n yd i ﬀerent
scientiﬁc journals to have access to the medical community
about the role of aneuploidy and genomic instability in the
genesis of Rb [4, 5, 39]. We are still optimistic, however,
because our alternative pathogenetic explanation has ﬁnally
appeared in recent ophthalmologic literature [40].
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